❖ Artificial nutrition and hydration (ANH) are common but controversial therapies at the end of life. Although widely used in certain patient populations, strong scientific evidence regarding the benefits of these therapies is lacking. Because of their important roles in teaching patients and families, and collaborating with team members, palliative and hospice nurses need to know and understand the clinical, ethical, and legal implications in providing or foregoing ANH. This article reviews the literature on the clinical benefits and burdens of ANH. The goal is to provide nurses with accurate information to promote good decision-making at the end of life. P rovision of food and fluids is a fundamental caregiving activity. From birth to death, eating and drinking are important opportunities for human contact and nurturing. For these reasons, the issues that arise when persons with progressive, life-limiting illnesses refuse or cannot take oral nourishment and fluids are emotionally complex and challenging. Deciding whether or not to initiate artificial nutrition and hydra-tion (ANH) often is an important topic of discussion in these circumstances. Patients and families must consider all options given their values and beliefs, the patient's prognosis, and clinicians' recommendations. Decisions regarding ANH often are made in highly charged situations in which the decision-makers are concomitantly trying to cope with multiple losses and grief.
Unfortunately, clinicians do not always make the process easier for patients and families. Healthcare providers may be guided by personal biases and beliefs that have a weak empirical basis. Another challenge for clinicians, as well as patients and families, is the shift in attitudes and practices in end-of-life care. As care for dying patients moved from an acute care focus to hospice, and more recently, to a broader, palliative care model, the use of ANH has changed remarkably. For example, Burge called intravenous fluids a "medical last rite," 1 reflecting the once widespread practice of hydrating dying patients without careful consideration of the expected outcomes or potential burdens of such therapy. Similarly, the use of artificial nutrition, particularly for people with advanced dementia, became widespread over the past few decades. 2, 3 As the hospice movement gained momentum, therapies such as ANH that were once applied without question came under scrutiny. The acute care model of "universal hydration" then shifted to the hospice model of "universal nonhydration." 4 Some authors have argued that neither end of the spectrum of ANH use is appropriate. As healthcare delivery models continue to evolve, palliative care may reconcile these two ends of the practice spectrum and identify appropriate uses of ANH for select groups of patients. 4 Until the pendulum swings back to a new equilibrium point, the rhetoric surrounding ANH is likely to remain polarized; some authors (who now appear to be in the minority) express discomfort about the inhumanity of "starving" people or allowing them to languish without proper attention to basic human needs. Others criticize a decision to initiate ANH as misguided or cruel, because they believe that subjecting dying patients to invasive, uncomfortable medical procedures is unwarranted; moreover, they argue, a death free from ANH will inevitably be peaceful and symptom-free. Neither perspective is firmly based on evidence drawn from well-designed prospective studies of palliative care and hospice patients. Until clinical experience and research are better able to guide the judicious use of ANH in selected patients, care providers must familiarize themselves with the current clinical, legal, and ethical issues regarding ANH, knowing that there are still areas of considerable uncertainty and debate.
To assist palliative and hospice nurses in this task, this article provides a comprehensive review of the clinical benefits and burdens of ANH. This analysis is organized according to the goals of therapy. A follow-up article will address the legal and ethical issues regarding ANH.
❖ DEFINITIONS
Artificial nutrition is any nonoral means of administering nutrition to a person. Methods encompass both enteral and intravenous (ie, total parenteral nutrition, TPN; also referred to as hyperalimentation) routes of administration. Enteral feeding is administered by tube via several routes: nasogastric, gastrostomy, jejunostomy, and esophagostomy. Often, enteral nutrition is called "tube feeding." In patients receiving palliative care, enteral feeding tubes typically are inserted at the bedside (eg, nasogastric) or via endoscopy (eg, percutaneous endoscopic gastrostomy, PEG; percutaneous endoscopic jejunostomy, PEJ). TPN is used less frequently than enteral feeding, in part because it is more expensive than using the gastrointestinal route and is associated with complications such as infection and sepsis, venous thrombus, hypoglycemia, and hyperglycemia. 5 Artificial fluid therapy involves the nonoral delivery of fluid through one of the following routes: intravenous (via a peripheral or central line), subcutaneous (also called hypodermoclysis), rectal (proctoclysis), or enteral. 5 It is also called "rehydration therapy" 6, 7 and is most commonly used to prevent or treat clinical problems associated with dehydration.
❖ CLINICAL GOALS OF ANH: RATIONALE AND EVIDENCE
Several authors have reported the beneficial and adverse outcomes of ANH. Many of these reports, however, are based on clinical impression, case studies, or retrospective chart reviews. Viola et al's excellent review of fluid status and fluid therapy at the end of life clearly details the many methodological problems with the research in this area. 8 Problematic methodologies include dissimilar comparison groups or lack of control or comparison group, nonrandom assignment to treatment, unblinded data collection, small sample sizes, and failure to control for con-founding variables. Similar deficits are found in the research on artificial nutrition. Moreover, the reports involve diverse groups of patients in a variety of clinical settings. For all these reasons, firm conclusions cannot be drawn. However, the existing research does provide some guidance regarding the potential benefits of ANH. The following discussion reviews this research.
ANH is designed to meet several therapeutic goals. These objectives include increased survival, prevention of aspiration and pressure sores, and increased comfort and amelioration of symptoms associated with malnutrition (eg, hunger) and dehydration (eg, thirst, delirium).
Tube feeding often is used to prevent aspiration-and its concomitant complication of pneumonia-in patients who have dysphagia secondary to neurological diseases, including advanced dementia. However, aspiration pneumonia is not decreased with gastrostomy or jejunostomy tubes, and in fact may be increased. Peck et al 9 found that aspiration pneumonia occurred significantly more often in a group of demented nursing home residents on long-term tube feeding, when compared with a random sample of residents who did not receive tube feeding (58% vs 17%, respectively). Langmore et al 10 used multivariate analyses to identify risk factors for aspiration pneumonia among 189 elderly patients with a variety of medical diagnoses. They found that tube feeding significantly increased the risk of aspiration pneumonia (Odds ratio: 3.031; p ϭ .05). Kadakia et al 11 retrospectively examined the incidence of aspiration pneumonia in 79 patients (mean age: 60; range 8-90 years) with long-term PEG or PEJ tubes. The most common indications for tube placement were neurologic disorders (58%) and cancer (23%). From their findings, the authors concluded that PEG/PEJ placement did not prevent aspiration. Finucane 12 reached the same conclusion in his literature review. Other authors also have discredited the idea that feeding through jejunostomy tubes confer some protection against aspiration pneumonia when compared with gastrostomy tubes, arguing that research does not support this belief. 9, 13, 14 Malnutrition is described as a risk factor for development of pressure sores and impaired wound healing. [15] [16] [17] Because pressure sores and other wounds can impair quality of life by causing pain, infection, and odor, artificial nutrition is sometimes used to prevent or reverse malnutrition, which in turn may protect against the development of pressure sores and enhance healing. Finucane 18 reviewed the empirical literature and found no prospective randomized trials that clearly showed the advantage of tube feeding for preventing or healing pressures sores. Peck et al 9 compared the incidence of pressure sores in nursing home residents who were tube fed with residents who were not; they found no significant difference between the 2 groups.
The prolongation of life generally is not considered a major goal in palliative and hospice care. However, some groups of patients and surrogate decision-makers have identified prolonged life as a major reason that they would choose ANH, specifically tube feeding. 19, 20 In addition, ANH is sometimes administered for this purpose to patients with acute, life-threatening illness. For these reasons, survival and ANH have been examined in long-term and acute care settings.
Mitchell et al 21 examined 2-year survival among 1386 older (Ͼ 65 years) nursing home residents, 9.7% of whom underwent tube-feeding placement. They found no survival advantage in tube-fed nursing home residents with severe cognitive impairment even after adjusting for potential confounding variables such as older age (Ͼ 87 years), aspiration, functional impairment, and DNR status. The investigators concluded that tube feeding did not prolong survival in nursing home residents. In a more recent, systematic review, Mitchell and Tetroe 22 pooled survival data from several studies and found no survival benefit associated with PEG placement. They also reported that overall 1-month survival for people with PEG tubes was 81%; 6-month survival, 56%; and 1-year survival, 38%. Factors most frequently associated with poorer survival among patients with PEG tubes included advanced malignant disease and older age. 22 Despite the lack of evidence that enteral nutrition prolongs survival in most patients, 2 studies suggest that specific groups of patients may experience longer survival with tube feeding. Mazzini and colleagues 23 compared survival among people with amyotrophic lateral sclerosis who received enteral nutrition via a PEG tube with those who did not. They found that the group receiving tube feeding had a statistically significant long-term (ie, 1 year) survival advantage compared with the group without tube feeding. In another study, Kaw and colleagues 24 performed a retrospective chart review of outcomes in nursing home residents, and noted that no patient younger than 40 years died in the first year following PEG tube placement; on the other hand, none of these younger patients demonstrated functional improvement, suggesting that prolonged survival is not always consistent with improved quality of life.
Cowen et al 25 performed a retrospective chart review to identify factors associated with survival among hos-pitalized patients who were unable to ingest sufficient food secondary to swallowing dysfunction. They found that overall 1-year mortality was high (62%). They also compared the mortality of patients with and without PEG tubes, and found that patients with PEG tubes, on average, survived longer than those without (181 vs 33 days, respectively). This statistically significant improvement in survival, however, may not be clinically meaningful because the comparison group (n ϭ 51) included patients who died before a PEG was inserted (n ϭ 12) and those who refused (or whose families refused) the therapy (n ϭ 28). This latter group likely included many patients whose poor prognosis led to the refusal. In other words, the patients who received PEG tubes may have had better prognoses unrelated to receiving artificial nutrition. Although the authors made statistical adjustment for 4 other variables associated with survival (eg, age, comorbidity), the groups may not have been comparable. More important, the quality of life among survivors was not measured; thus, the quality of the extended life is unknown. 26 In a large, multisite study of treatment outcomes in hospitalized adults with serious illness, enteral feeding and TPN were not associated with prolonged survival in patients with cancer. In fact, these therapies were associated with decreased survival in patients with multiorgan system failure, COPD, sepsis, acute respiratory failure, and cirrhosis. Only for comatose patients were enteral feeding and TPN associated with prolonged survival. 27 Koretz's review of the effects of TPN in cancer patients revealed that only 1 of 14 randomized clinical trials of parenteral nutrition demonstrated any improvement in survival. 28, 29 Generally, the empirical literature does not support the effectiveness of ANH in prolonging life. In fact, some authors cite the high mortality rates among patients receiving tube feeding as a primary reason for questioning the appropriateness of this therapy. 24, 30, 31 Moreover, tube placement may itself result in death from complications. Finucane's review of PEG use in patients with dementia yielded mortality rates of 0% to 2% during tube placement and 6% to 24% perioperative mortality rates. 31 Although TPN-associated mortality rates are unknown, the morbidity associated with TPN is estimated at 15%. 28 Palliative and hospice care is guided by a central goal of enhancing comfort and quality of life for dying patients. Does ANH accomplish this goal? Tube feeding may be initiated to control hunger in malnourished patients with life-threatening illness. However, several authors have documented that hunger is uncommon in patients at the end of life. McCann et al 32 monitored 32 patients during their stay on a comfort-care unit within a long-term care setting. Patients were not able to meet basic nutritional requirements through eating. They found that 64% of patients did not experience hunger at any time, 34% experienced hunger only initially, and 3% experienced hunger throughout their stay. When hunger was reported, it was ameliorated by providing small amounts of food. 32 In their study of 31 patients with amyotrophic lateral sclerosis, Scott and Austin 33 reported that hunger and nausea began or became worse following feeding tube placement.
General discussions of dehydration often catalogue a long list of troubling symptoms that can negatively affect comfort and quality of life ( Table 1 ). Many of these symptoms have been identified in studies of healthy volunteers undergoing experimental fluid deprivation. 34 Clinicians working with terminally ill patients, however, report that few patients experience these symptoms at the end of life. [35] [36] [37] [38] [39] Moreover, some authors describe several hypothetical benefits of terminal dehydration, including analgesia, 36, 39, 40 less frequent need to void, 36 and fewer episodes of incontinence. 36 Zerwekh also maintained that dehydration decreases respiratory secretions. McCann et al 32 concluded that decreased fluid intake resulted in decreased secretions, although the data on which this assertion is based are not documented. In contrast, Ellershaw and colleagues were unable to find a relationship between fluid status and respiratory secretions. 41 These purported benefits of dehydration at the end of life, then, have not been confirmed through research.
Thirst and dry mouth are common EOL symptoms, occurring in 66% to 95% of terminally ill patients. 32, [41] [42] [43] In theory, adequate hydration should prevent or ameliorate these symptoms, thereby providing a rational for using parenteral fluids for comfort. However, studies have not found a relationship between thirst and biochemical signs of dehydration such as serum sodium, blood urea nitrogen, and osmolality. 41, 43, 44 Nor is there a relationship between thirst and fluid intake. 43, 44 Some authors assert that thirst and dry mouth are effectively treated with simple, noninvasive measures such as regular mouth care, ice chips, small amounts of fluids, and artificial saliva. 32, 34, 35, 45 In contrast to many palliative care and hospice services, clinicians at the Edmonton Palliative Care Program routinely use rehydration therapy for several purposes, including the relief of confusion and delirium and the enhance-ment of glomerular filtration, which in turn mitigates the adverse effects associated with the accumulation of opioid metabolites (ie, confusion, myoclonus, nausea, and seizures). 46, 47 Although the group vigorously defends their practice, there are few data to support their conclusions regarding the salutary effects of rehydration. For example, Fainsinger et al 48, 49 noted that less sedation is needed to treat agitated delirium when rehydration is routinely employed; however, this observation may also be due to other therapeutic measures that are routinely used in their ❖ ❖ ❖ ❖ ❖ patients, such as opioid rotation. The Edmonton group also has extolled the benefits of using hypodermoclysis (HCD) for rehydration. 46 However, there are no data presented to evaluate the clinical goals of therapy. Instead, the authors show that normal creatinine and BUN were achieved, outcomes that are not correlated with patient comfort or amelioration of symptoms. 41, 43, 44 Moreover, they report that the HCD site was changed a total of 80 times in 69 patients. Common reasons for site change included inflammation, bleeding, and bruising. Based on the evidence presented, the rationale for rehydration is unclear.
❖ RISKS AND COMPLICATIONS OF ANH
Many authors have documented the risks and burdens of ANH. Some risks have been documented in studies (Table 2) . Others are based on clinical impressions that need to be verified through research.
The major complications associated with tube feeding are aspiration and mortality, although no randomized trials have documented whether or not feeding actually increases aspiration and mortality. 12, 31 There is considerable morbidity associated with enteral and parenteral tubes. These complications are well documented and include bleeding, infection, skin excoriation, and tube dislodgment. 13 Some authors have observed that tube feeding seems to cause or exacerbate nausea, vomiting, and diarrhea. [50] [51] [52] Only one study, however, provided empirical validation that tube feedings are associated with greater hunger and nausea. 33 Cogen et al reported that diarrhea occurred in 23% of patients fed by jejunostomy. 13 Decreased human contact may also occur because patients are denied the socialization that comes with mealtimes. 33, 53, 54 They also lose the pleasure of eating; this loss is especially likely when patients are capable of eating some food, but unable to ingest adequate nutrients. 55 Artificial fluid therapy is thought to increase peripheral and pulmonary edema, circulatory overload, and possibly respiratory secretions. 32, 36, 37 Two studies, however, failed to find a relationship between intravenous fluid intake and signs of fluid retention. 41, 56 Fluid therapy is most likely to cause symptomatic fluid overload in patients with severe hypoalbuminemia, or cardiac or renal dysfunction. 34, 57 One compelling argument against ANH is that it requires the use of restraints, especially in patients who are confused or demented who are at risk of dislodging tubes. 53, 58, 59 In a study of elderly nursing home residents, Sullivan-Marx and colleagues found that use of treatment devices such as gastrostomy and intravenous tubes was significantly associated with restraint use. 59 Similarly, Peck and associates found that demented nursing home residents with enteral feeding tubes were more likely to be restrained than residents without such devices. 9 Although further documentation regarding the risks and complications is necessary, it appears that in many cases, the results of ANH run counter to its intended purpose. That is, instead of prolonging survival, decreasing aspiration, ameliorating end-of-life symptoms such as pain and nausea, and enhancing comfort, ANH decreases the quantity and quality of life for dying patients. In the absence of strong evidence supporting the benefits of ANH, palliative care and hospice nurses need to consider the potential burdens and educate patients and families regarding potential outcomes of ANH.
❖ NURSING IMPLICATIONS
Patient and family education is a central role for nurses. ANH is a treatment that frequently is discussed at the end of life. Therefore, palliative care and hospice nurses should understand the empirical basis for recommendations about its use in order to provide accurate, unbiased information. Readers should be aware that there is controversy about the effectiveness and risks of ANH, and definitive empirical evidence to guide clinical decision-making is lacking. In general, the currently available evidence supports the conclusion that ANH has very limited clinical utility for most patients at the endof-life. Moreover, the treatment itself can result in increased morbidity and mortality. However, ANH may be clinically beneficial in specific situations. Future research may lead to a redefinition and refinement of situations in which ANH is clinically appropriate.
In addition to teaching about the risks and benefits of ANH, education should also encompass information about the dying process. Patients and families should know that decreased interest and ability to take food and fluids by mouth is a natural part of the dying process. Families should be reassured that lack of oral intake does not result in discomfort for most patients. Caregivers should be taught how to provide comfort to the patients through measures such as frequent oral and skin care and massage.
Potential risks and benefits should take into account the possible trajectory of the patient's illness. Huang and Ahronheim 60 described the utility of Lynn's 3 common terminal illness trajectories: (1) the person retains the ability to perform activities of daily living and decision-making capacity (eg, many patients with terminal cancer); (2) the person experiences chronic illness and disability with recurrent exacerbations-the exact timing of death is unpredictable (eg, people with chronic heart, lung, liver, and renal failure); and (3) the person experiences progressive disability and is often incompetent for months to years prior to death (eg, people with stroke, dementia, or general frailty). 61 These categories may provide a useful framework for considering treatment options, including ANH. For example, an acute but nonfatal exacerbation of congestive heart failure is more likely to be a clinically appropriate situation to provide a time-limited trial of tube feeding. Similarly, a patient with advanced cancer may benefit from fluid therapy to maintain physiologic stability while undergoing palliative chemotherapy. These classifications also assist clinicians in understanding the limitations of the empirical evidence for ANH. For example, studies regarding the benefits of fluid therapy have focused predominantly on cancer patients. 46, 47 Thus, the findings may not apply to patients with dementia or chronic organ failure.
Nurses also should provide guidance to patients and families in decision-making that includes evaluation of the patient's current condition and prognosis, accurate clinical information, a clear and complete discussion of treatment options, and consideration of the patient's and family's values and beliefs about dying, death, family roles, and nurturing as well as their goals for care.
Decision-making about ANH also should incorporate input from healthcare providers with expertise in evaluating and treating swallowing and nutritional disorders. These professionals include speech therapists and nutritionists who are able to identify and implement strategies that enable patients to take oral nutrition and fluids safely and effectively, as an alternative to ANH. 55, 62 Clinicians also should be aware that the manner and context in which information is provided influences the decisions that are made. For example, Callahan et al 63 examined the decision-making process of 100 older adults (or their surrogates) regarding gastrostomy tube placement. They reported that the majority of discussions about enteral feeding were initiated in the context of an acute medical event that usually required hospitalization. Forty-five percent of informants reported that no alternatives to gastrostomy tube placement were presented, and many commented that they felt as though the decision was a "foregone conclusion." 63(p1107) Bruera and MacDonald 64 describe another example of how clinicians' practices and biases influence patient and family decision-making. They described a study that compared the rates of artificial hydration in 2 clinical settings in Canada. In one setting, all patients agreed to artificial hydration, whereas none of the patients in the other setting agreed to hydration therapy. Not surprisingly, clinicians practicing in the first setting included hydration as part of their normal practice, and the clinicians in the second setting rarely included ❖ ❖ ❖ ❖ ❖ 68 pointed out that despite the lack of compelling evidence for the benefits of tube feeding, 10% of severely demented nursing home residents in the United States receive this intervention. 2, 21 She posited that current Medicare and Medicaid reimbursement for nursing home care may inappropriately provide fiscal incentives for tube placement. Based on her analysis, Mitchell encouraged the modification of reimbursement policies to allow adequate payment for hand feeding of severely debilitated patients. The editorial also cited a study by Meier and colleagues 69 in which they found that 50% of older patients with advanced dementia received feeding tube placement during hospitalization for acute conditions. Mitchell speculated that efforts to shorten hospital stays might result in hurried decisions to place feeding tubes. 68 This article reminds nurses and other clinicians to advocate for patients at end of life to ensure that decisions about ANH and other therapies are based on patient preferences and needs rather than on fiscal considerations.
❖ SUMMARY
This article reviewed the evidence regarding the clinical benefits and burdens of ANH. Artificial nutrition and hydration are frequently employed in the care of seriously ill patients to achieve several clinical outcomes, including enhanced survival and quality of life. The ability to achieve these outcomes, however, is unsupported by research for many patients at the end of life. The current evidence, although deficient in many areas, indicates that ANH is not likely to promote comfort and enhance quality of life for most terminally ill persons. Research has yet to define the situations in which ANH promotes comfort and quality of life in persons with life-limiting, progressive illness. Nonetheless, it is possible that as palliative care extends the "typical" period of care well beyond the last 6 months of life, clinicians and researchers may identify novel, appropriate uses for ANH. Clinicians should provide patients, families, and the public with accurate information regarding the benefits and burdens of ANH. They also need to understand the social, ethical, and financial factors that influence ANH use.
